[Hematopoietic cells raising with plerixafor in non-Hodgkin lymphoma]. [Movilización de células hematopoyéticas con plerixafor en linfoma no Hodgkin folicular.]
Por:
Pérez-Lozano U., Tripp-Villanueva F., Ramírez-Alvarado A., Vela-Ojeda J., Limón-Flores A., Kramis-Cerezo J.L.
Publicada:
1 ene 2012
Categoría:
Medicine (miscellaneous)
Resumen:
bone marrow autologous transplantation (BMAT) has proven benefits in patients treated for non-Hodgkin's lymphoma (NHL). Plerixafor is an inhibitor of CXCR4 receptor. The aim was to report the raise of hematopoietic cells with plerixafor in patients with NHL. patient 1 with follicular NHL, GI, intermediate FLIPI, CD20+, CD45+, BCL-2+, who reached complete response after three chemotherapy regimes. Mobilization failed after use of filgrastim (G-CSF) alone and G-CSF + cyclophosphamide. A new attempt was made with G-CSF + plerixafor (G-CSF, 10 µg/kg for 7 days + plerixafor, 240 µg/kg in days 4 to 7). Patient 2 with follicular NHL and CD20+ reached complete remission with MINE after therapeutic failure with other regimes, but develops severe marrow toxicity. Mobilization was supported with G-CSF 10 µg/kg/d + plerixafor in days 4 and 5. In case one, proper cell counts where obtained after three aphaeresis. In the second case, two harvests add of 2.7 × 106/kg were obtained. plerixafor raised the hematopoietic stem cells in peripheral blood and improves mobilization of proper cell population.
Filiaciones:
Pérez-Lozano U.:
Servicio de Hematología, Hospital de Especialidades, Puebla Instituto Mexicano del Seguro Social, Puebla, Mexico
|